Physics and imaging in radiation oncology · 2026
Base of tongue volume and dose as predictors of late dysphagia after definitive or adjuvant radiotherapy for oral cavity squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Azria Joseph, Beddok Arnaud, Brenet Esteban, Antoni Delphine, Auzeau Laurence, Assouly Nathaniel, Fontaine Marine, Guendouzen Sofiane, Merol Jean-Claude, Merrouche Yacine, Guilbert Philippe, Da Silva Ribeiro Mota Antonio
Аннотация
BACKGROUND AND PURPOSE: Radiation-induced dysphagia is a major determinant of quality of life in patients treated for oral cavity squamous cell carcinoma (OCSCC). While dose to the pharyngeal constrictor muscles has been extensively investigated, the base of tongue (BOT) remains poorly studied. This study aimed to evaluate the association between BOT volume and dose-volume parameters and late dysphagia.
MATERIAL AND METHODS: Fifty-two patients with OCSCC treated with volumetric modulated arc therapy (VMAT) between 2019 and 2023 were retrospectively analyzed. All patients had a prophylactic feeding tube (FT) placed before VMAT. The base of tongue was delineated using an artificial intelligence-based segmentation algorithm and reviewed by a senior radiation oncologist. Late dysphagia was defined as prolonged FT dependency using the cohort-specific 75th percentile (> 442.5 days). Volumetric and dose/volume parameters of the BOT (D0%-D100%) were analyzed using logistic regression, receiver operating characteristic (ROC) curve analysis, and Kaplan-Meier methods.
RESULTS: The median BOT volume for the entire cohort was 18.4 cm3 (interquartile range [IQR]: 15.7-21.3 cm3). Patients with late dysphagia had smaller BOT volumes than those without (15.9 vs. 19.5 cm3, p = 0.02). A BOT volume < 19.12 cm3 was associated with increased dysphagia risk. No dose/volume parameter reached statistical significance, although a trend suggested lower risk for a BOT D50% < 52.2 Gy (p = 0.21). A combined model integrating BOT volume and D50% achieved an area under the curve (AUC) of 0.74 (95% CI: 0.61-0.87).
CONCLUSIONS: Smaller BOT volume was associated with increased risk of prolonged FT dependency after radiotherapy for OCSCC. BOT dose metrics were not significant but showed hypothesis-generating trends that warrant validation in larger cohorts and dose-optimization studies.
MATERIAL AND METHODS: Fifty-two patients with OCSCC treated with volumetric modulated arc therapy (VMAT) between 2019 and 2023 were retrospectively analyzed. All patients had a prophylactic feeding tube (FT) placed before VMAT. The base of tongue was delineated using an artificial intelligence-based segmentation algorithm and reviewed by a senior radiation oncologist. Late dysphagia was defined as prolonged FT dependency using the cohort-specific 75th percentile (> 442.5 days). Volumetric and dose/volume parameters of the BOT (D0%-D100%) were analyzed using logistic regression, receiver operating characteristic (ROC) curve analysis, and Kaplan-Meier methods.
RESULTS: The median BOT volume for the entire cohort was 18.4 cm3 (interquartile range [IQR]: 15.7-21.3 cm3). Patients with late dysphagia had smaller BOT volumes than those without (15.9 vs. 19.5 cm3, p = 0.02). A BOT volume < 19.12 cm3 was associated with increased dysphagia risk. No dose/volume parameter reached statistical significance, although a trend suggested lower risk for a BOT D50% < 52.2 Gy (p = 0.21). A combined model integrating BOT volume and D50% achieved an area under the curve (AUC) of 0.74 (95% CI: 0.61-0.87).
CONCLUSIONS: Smaller BOT volume was associated with increased risk of prolonged FT dependency after radiotherapy for OCSCC. BOT dose metrics were not significant but showed hypothesis-generating trends that warrant validation in larger cohorts and dose-optimization studies.